Axon Enterprise has seen a 110,600% increase in stock value and is highly recommended by analysts.

From Nasdaq, Inc.: 2024-12-27 03:02:00

The Nasdaq Composite is a key U.S. stock market index tracking around 3,000 tech-focused stocks. Axon Enterprise (NASDAQ: AXON) recently joined the Nasdaq-100, replacing Moderna, with a 110,600% stock increase since its IPO. Axon is known for its Taser stun gun, body cameras, and cloud services, reporting 32% revenue growth in the third quarter. Analysts are bullish on Axon, with all 15 covering analysts rating it a buy. Despite a high valuation, Axon’s growth prospects and track record make it a strong investment opportunity. Management raised full-year revenue outlook to $2.07 billion, representing a 32% growth.



Read more at Nasdaq, Inc.: Meet the Newest Stock in the Nasdaq-100. It’s Soared 110,600% Since Its IPO and It’s Still a Buy Heading Into 2025, According to Wall Street.